Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Altimmune, Inc.NASDAQ: ALT

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense turns positive

Q1 FY2026 income tax expense was $0, compared with -$681K a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense amounted to 1661.0% of revenue in FY2025, up 1661.0 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
-$681K— YoY
LTMMar 2026
$0+100.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(681K) USD
Year-over-year change
—

Income Tax Expense vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.0% is the 3rd highest of 6, against a peer median of +51.1%.
  • Income tax expense amounts to 0.0% of revenue for ALT, versus a peer median of 0.1%.
ALT Competitors
Income Tax Expense for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$702.57K USD+51.1%+211.7%—
VIRVir Biotechnology, Inc.LTM Mar 2026$371K USD+126.4%-90.3%0.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$92K USD+103.7%—0.1%
IVAInventiva S.A.FY2025€22K EUR-93.0%—0.5%
ALTAltimmune, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
ABUSArbutus Biopharma CorporationLTM Mar 2026$0 USD——0.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ALT) —+51.1%+60.7%0.1%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.